Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial | ACHFF Stock NewsStockTitan·Mar 24 at 12:13 AMARTH0.00%XBI-3.64%
Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT PeptideGlobeNewswire·Mar 20 at 06:05 AMPBE-1.73%FBT-1.38%
Arthrex Releases TightRope® SB All-Suture Implant for ACL FixationMorningStar·Feb 26 at 12:10 PMARTHQ0.00%XBI-3.64%
Arthex Biotech's ATX-01 promising for DM1 per American Journal of Human Genetics; miR-23b target shows benefits.Unusual Whales·Feb 25 at 02:03 AMCS精准医+6.30%ARTHQ0.00%
